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Increased risk of incident primary cancer after
Staphylococcus aureus bacteremia
A matched cohort study
Nanja Gotland, MDa,
∗
, M.L. Uhre, MDa, H. Sandholdta, N. Mejer, MD, PhDa, L.F. Lundbo, MD, PhDa,
A. Petersen, MDb, A.R. Larsen, MDb, T. Benfield, MD, DMSca,c
Abstract
Susceptibility to infectious disease may be a marker of immunodeficiency caused by unrecognized cancer. To test the hypothesis,
the risk of incident primary cancer was estimated among survivors of Staphylococcus aureus bacteremia (SAB) and compared to a
random population cohort.
Nation-wide population-based matched cohort study. Cases of SABwere identified from a national database and incident primary
cancers were ascertained by record linkage. Incidence rate (IR) and ratio (IRR) with 95% confidence interval (CI) of 27 cancers was
calculated by Poisson regression.
During the first year of follow-up, 165 and 943 incident cases of cancer occurred in the case cohort (n=12,918 (1.3%)) and the
population cohort (n=117,465 (0.8%)) for an IR of 3.78 (3.22–4.40) and 2.28 (2.14–2.43) per 100,000 person-years. The IRR was
1.65 (1.40–1.95). Of 27 cancers, 7 cancers occurredmore frequently amongst cases than controls: cervical cancer (IRR 37.83 (4.23–
338.47)), multiple myeloma (IRR 6.31 (2.58–15.44)), leukemia (IRR 4.73 (2.21–10.10)), sarcoma (IRR 4.73 (1.18–18.91)), liver cancer
(IRR 3.64 (1.30–10.21)), pancreatic cancer (IRR 2.8 (1.27–6.16)), and urinary tract cancer (IRR 2.58 (1.23–5.39)). Compared to the
control population, the risk of cancer was higher for those without comorbidity and with younger age. The overall risk of cancer during
2 to 5 years of follow-up was not increased (IRR 0.99 (95% CI: 0.89–1.11). However, the risk of pharyngeal cancer was increased
(IRR 1.88 (1.04–3.39)) and the risk of liver cancer remained increased (IRR 3.93 (2.36–6.55)).
The risk of primary incident cancer was 65% higher in the SAB cohort compared to the population cohort during the first year of
follow-up and included 7 specific cancers. The risk was higher for those without comorbidity and with younger age. Screening for
these specific cancers in selected populations may allow for earlier detection.
Abbreviations: CI = confidence interval, IR = incidence rate, IRR = incidence rate ratio, mCCI =modified Charlson Comorbidity
Index, PYs = person years, SAB = Staphylococcus aureus bacteremia.
Keywords: bacteremia, cancer, Staphylococcus aureus
1. Introduction
More than 1 in 3 persons will be diagnosed with cancer during a
lifetime and cancer ranks as 1 of the 2 most frequent causes of
death in high-income countries.[1] Early detection is essential to
improve outcome of cancer. Up to 20% of all cancers are
associated with microbial coinfection, suggesting that immunity
and inflammation play a role in cancer development.[2–5] The
association of impaired immune function, microbial coinfection
and cancer is well described in the context of HIV infection and
organ transplantation.[6] Non-microbial–associated tumors, such
as skin and thyroid cancer, have been associated with iatrogenic
immunosuppression.[7]
Based on these observations, we hypothesized that a developing
cancer may be preceded by an increased susceptibility to invasive
bacterial infection due to impending immunodeficiency. In a recent
study, we showed that individuals with Staphylococcus aureus
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bacteremia (SAB) were more likely to die from cancer than the
general population during long-term follow-up, supporting the
concept that SABmay be an early indicator of cancer.[8] To test our
hypothesis,weusedanationwidematchedcohort study to estimate
rates of 27 types of cancer occurring after SABand compared these
to a population cohort without SAB.
2. Methods
2.1. Study design
Anation-wide population-basedmatched cohort study consisting
of a cohort of survivors of SAB and a comparison cohort of
random population control. Cases of SAB were identified from
the Danish Staphylococcal Bacteremia Database[9] and incident
primary cancers were ascertained by record linkage to the Danish
Cancer Registry.[10,11] The case cohort comprised individuals at
risk of incident cancer, i.e. alive, without a cancer diagnosis, and
discharged after a first episode of SAB. The comparison cohort
included up to 10 population controls that were randomly
selected from the Civil Registration System matched to the
corresponding case on age and sex. Controls had to be alive and
without a cancer diagnosis on the date of the cases discharge.
Individuals were excluded from both cohorts if they died,
emigrated, were lost to follow-up or were diagnosed with cancer
within the first 90 days of discharge.
Follow-up time was calculated from 91 days after discharge
and censored on the date of emigration, loss to follow-up, date of
diagnosed cancer or January 19, 2015, whichever came first.
Population controls were assigned the index date of their
corresponding case. The study was conducted in accordance with
the STROBE statement.[12]
2.2. Setting
All regions of Denmark from January 1992 to October 2014. All
cases of SAB during the study period were included.
2.3. Data sources
The Civil Registration System,[13] the Danish Staphylococcal
Bacteremia Database[9] and the Danish National Patient
Register[14] have been described previously.[8] Prevalent and
incident cancers were identified using the Danish Cancer Registry
that registers 98% of all cancers in Denmark.[10,11] Since 1987,
all physicians in hospitals and private practices have been
required by law to report all diagnoses of cancer to the registry.
All diagnoses are assigned based on histologic examination by a
fully trained pathologist. The registry uses a conservative strategy
to avoid misclassification of relapse of the first cancer and records
only true occurrence of a second primary cancer of the same
type.[15] We classified diagnoses into 27 categories according to
the ICD 7th edition codes 140.0–207.0 for the period 1992–
2003, and ICD 10th edition codes C00.0–C96.0 and D00.0–
D09.0 for the period 2004–2014 (Supplementary Table 1, http://
links.lww.com/MD/E116).[16]
2.4. Statistics
Statistical analyses were performed using R software version
3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).
A modified Charlson Comorbidity Index (mCCI) score (cancer
excluded) was constructed using all discharge data prior to
hospitalization for SAB.[17,18] The score considers both the
number and severity of comorbid disease. Each of the 15
categories of CCI could only contribute once to the overall index.
We defined 3 levels of comorbidity: None, intermediate (1–2) and
high (>2).
Crude incidence rate was estimated as the number of incident
cancer divided by person years (PYs) at risk with corresponding
95% confidence interval (CI), computed using a Poisson
distribution. Incidence rate (IR) and ratio (IRR) with 95% CI
was estimated by Poisson regression.
To assess the competing event of death, survival curves were
estimated by the cumulative incidence function. In order to
account for inverse causality, the case and population cohorts
were left-censored for the first 3 months.
2.5. Ethical considerations
The study was approved by the Danish Data Protection Agency
(record no. 2014–41–3376). Danish legislation does not require
informed consent for register-based studies.
3. Results
3.1. Characteristics of the study populations
Of the27,901SABcases thatweredischarged fromJanuary1,1992
to October 31, 2014, 2046 were excluded due to an invalid sample
date or identifier, 6767 cases were diagnosed with cancer before or
during admission for SAB and 6170 died or had a cancer diagnosis
within 90 days of discharge. Of the corresponding comparison
cohort, 230 controls were excluded due to an invalid sample
date, 52,728 controls were excluded because their corresponding
case had a cancer diagnosis before, during admission, or within
the first 90 days of admission, and 358 controls had a cancer
diagnosis within 90 days after the corresponding cases discharge.
Thus, 12,918 cases and 11,7465 population controls were
included in the analysis (Table 1 and Fig. 1).
The majority of the case cohort was male (63.1%), older than
55 years (57.0%) and had had a hospital contact within 90 days
before SAB (68.0%). The case cohort had more comorbidity
compared to the comparison cohort (Table 1).
The median follow-up time was 4.35 (IQR 1.59–9.38) years
for the SAB cohort and 7.43 (IQR 3.20–13.92) years for the
population cohort.
3.2. Risk of incident cancer
During the first year of follow-up, 165 (1.3%) cases (IR 3.78
(3.22–4.40) per 100,000 PYs) and 943 (0.8%) controls (IR 2.28
(2.14–2.43) per 100,000 PYs) were diagnosed with incident
cancer corresponding to a 65% increased risk (IRR 1.65 (1.40–
1.95)) (Table 2, Fig. 2). Of 27 types of cancer, 7 cancers occurred
more frequently amongst cases than controls: cervical cancer
(IRR 37.83 (4.23–338.47)), multiple myeloma (IRR 6.31 (2.58–
15.44)), leukemia (IRR 4.73 (2.21–10.10)), sarcoma (IRR 4.73
(1.18–18.91)), liver cancer (IRR 3.64 (1.30–10.21)), pancreatic
cancer (IRR 2.8 (1.27–6.16)), and urinary tract cancer (IRR 2.58
(1.23–5.39)).
3.3. Subsequent follow-up
From 2 to 5 years of follow-up, the overall risk of cancer was
comparable in the SAB (IR 2.39 (95% CI: 2.15–2.65)) and
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population cohort (IR 2.40 (95% CI: 2.33–2.48)) for an IRR of
0.99 (95% CI: 0.89–1.11) (Table 3). However, the risk of
pharyngeal cancer was increased (IRR 1.88 (1.04–3.39)) and the
risk of liver cancer remained increased (IRR 3.93 (2.36–6.55)).
3.4. Effect of sex, age, and comorbidity on risk of cancer
The risk of cancer during the first year of follow-upwas higher for
individuals with SAB, no prior comorbidity and for all age groups
(Table 4). Individuals with prior comorbidity had similar
incidences of cancer in the SAB and population cohorts
(Fig. 3A-C). Sex did not affect the incidence of cancer for the
SAB cohort compared to the population cohort. After adjustment
for age, sex and Charlson comorbidity index, the risk of cancer
remained increased for the SAB cohort compared to the
comparator cohort (IRR 1.84 (95% CI: 1.17–2.89).
4. Discussion
4.1. Main findings
In this large nationwide population-based cohort study, we found
that SAB was a marker of cancer. In particular, we found an
increased risk of 7 specific cancers during the first year after
hospitalization for SAB. After the first year, overall risk of cancer
was comparable in the case and population cohorts.
Table 1
Characteristics of the Staphylococcus aureus bacteremia and population cohorts.
SAB cohort Population cohort
All N=12,918 No Cancer N=11,975 Cancer N=943 All N=117,465 No Cancer N=106,190 Cancer N=11,275
Sex
Male 8,156 (63.1%) 7,529 (62.9%) 627 (66.5%) 74,627 (63.5%) 67,058 (63.1%) 7,569 (67.1%)
Female 4,762 (36.9%) 4,446 (37.1%) 316 (33.5%) 42,838 (36.5%) 39,132 (36.9%) 3,706 (32.9%)
Age, years
0-15 1,232 (9.5%) 1,224 (10.2%) 8 (0.9%) 12,305 (10.5%) 12,285 (11.6%) 20 (0.2%)
16-35 1,322 (10.2%) 1,277 (10.7%) 45 (4.8%) 13,165 (11.2%) 12,916 (12.2%) 249 (2.2%)
36-55 2,993 (23.2%) 2,789 (23.3%) 204 (21.6%) 29,135 (24.8%) 27,150 (25.6%) 1,985 (17.6%)
56-75 4,950 (38.3%) 4,463 (37.3%) 487 (51.6%) 44,090 (37.5%) 37,300 (35.1%) 6,790 (60.2%)
>75 2,422 (18.7%) 2,222 (18.6%) 199 (21.1%) 18,770 (16.0%) 16,539 (15.6%) 2,231 (19.8%)
mCCI score
∗
0 4,983 (38.6%) 4,635 (38.7%) 348 (36.9%) 90,697 (77.2%) 82,226 (77.4%) 8,471 (75.1%)
1-2 5,070 (39.3%) 4,661 (38.9%) 409 (43.4%) 23,785 (20.3%) 21,214 (20.0%) 2,571 (22.8%)
>2 2,865 (22.2%) 2,679 (22.4%) 186 (19.7%) 2,983 (2.5%) 2,750 (2.6%) 233 (2.1%)
Hospital contact within 90 days
Yes 8,790 (68.0%) 8,154 (68.1%) 636 (67.4%) - - -
No 4,128 (32.0%) 3,821 (31.9%) 307 (32.6%) - - -
Total follow-up, years
Median 4.35 (IQR:1.59–9.38) 7.43 (IQR:3.20–13.92)
Mean 6.30 (SD:5.83) 8.78 (SD:6.41)
∗
mCCI score = modified Charlson Comorbidity score (without cancer or metastasis).
SAB = Staphylococcus aureus bacteremia, IQR = interquartile range, SD = standard deviation.
Figure 1. Patient flow diagram.
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Table 2
Incident cancer during the first year of follow-up after Staphylococcus aureus bacteremia compared to a population cohort without
Staphylococcus aureus bacteremia.
Type of cancer SAB cohort N=165 Population cohort N=943 Incidence rate ratio with 95% confidence interval
Hodgkin’s lymphoma 0 0 -
Small Intestine cancer 0 1 (0.11%) -
Non-Hodgkin’s lymphoma 3 (1.82%) 11 (1.17%) 2.58 (0.72–9.25)
Thyroid cancer 1 (0.61%) 4 (0.42%) 2.36 (0.26–21.12)
Sarcoma 3 (1.82%) 6 (0.64%) 4.73 (1.18–18.91)
Testicular cancer 0 2 (0.21%) -
Multiple myeloma 8 (4.85%) 12 (1.27%) 6.31 (2.58–15.44)
Esophageal cancer 2 (1.21%) 10 (1.06%) 1.89 (0.41–8.63)
Laryngeal cancer NA 11 (1.17%) -
Liver cancer 5 (3.03%) 13 (1.38%) 3.64 (1.3–10.21)
Brain cancer 3 (1.82%) 10 (1.06%) 2.84 (0.78–10.32)
Kidney cancer 4 (2.42%) 25 (2.65%) 1.51 (0.53–4.34)
Pharyngeal cancer 3 (1.82%) 18 (1.91%) 1.58 (0.47–5.36)
Corpus uteri cncer 1 (0.61%) 10 (1.06%) 0.95 (0.12–7.42)
Stomach cancer 3 (1.82%) 12 (1.27%) 2.36 (0.67–8.36)
Leukemia 10 (6.06%) 20 (2.12%) 4.73 (2.21–10.1)
Ovarian cancer 0 12 (1.27%) -
Pancreatic cancer 8 (4.85%) 27 (2.86%) 2.8 (1.27–6.16)
Malignant melanoma 4 (2.42%) 22 (2.33%) 1.72 (0.59–4.99)
Urinary tract cancer 9 (5.45%) 33 (3.5%) 2.58 (1.23–5.39)
Cervical cancer 4 (2.42%) 1 (0.11%) 37.83 (4.23–338.47)
Prostate cancer 19 (11.52%) 136 (14.42%) 1.32 (0.82–2.13)
Breast cancer 8 (4.85%) 59 (6.26%) 1.28 (0.61–2.68)
Colon cancer 7 (4.24%) 123 (13.04%) 0.54 (0.25–1.16)
Lung cancer 22 (13.33%) 138 (14.63%) 1.51 (0.96–2.37)
Skin cancer 32 (19.39%) 219 (23.22%) 1.38 (0.95–2.00)
Other cancer 6 (3.64%) 8 (0.85%) 7.09 (2.46–20.43)
SAB = Staphylococcus aureus bacteremia.
Figure 2. Cumulative incidence of cancer in the case and population cohorts with 95%CI.
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4.2. Comparison with other studies
Few population-based studies have investigated the risk of cancer
following invasive bacterial disease. Søgaard et al showed an
increased risk of mainly gastrointestinal and genitourinary cancer
in a cohort of individuals with Gram negative bacteremia.[19] The
incidence of any cancer between 6 and 12 months after
bacteremia was estimated to be 1.46 higher than for controls;
a rate comparable to the 1.65 in our study. Similarly, Thomsen
et al showed an increased risk of any cancer of 1.75-fold from 4 to
12 month after a diagnosis of endocarditis.[20] The latter study
found an increased risk of leukemia andmyeloma but only during
the first 3 months after endocarditis while Søgaard et al did not
find any association between Gram negative bacteremia and
hematological cancer except non-Hodgkin lymphoma during the
first 6 month. These discrepancies suggest that different bacteria
may confer different risks of malignant disease. Several studies
suggest that this may be the case. The association ofHelicobacter
pylori and gastrointestinal lymphoma is well documented.[21]
Associations between non-hemolytic streptococci, Bacillus
fragilis, Fusobacterium nucleatum, Peptostreptococcus species,
Table 3
Incident cancer from 2 to 5 years of follow-up after Staphylococcus aureus bacteremia compared to a population cohort without
Staphylococcus aureus bacteremia.
Type of cancer SAB cohort n=371 Population cohort n=4103 Incidence rate ratio 95% confidence interval
Hodgkin’s lymphoma 1 (0.27%) 2 (0.05%) 5.5 (0.5–60.66)
Small Intestine cancer 0 8 (0.19%) -
Non-Hodgkin’s lymphoma 4 (1.08%) 58 (1.41%) 0.76 (0.28–2.09)
Thyroid cancer 2 (0.54%) 8 (0.19%) 2.75 (0.58–12.95)
Sarcoma 4 (1.08%) 31 (0.76%) 1.42 (0.5–4.02)
Testicular cancer 0 14 (0.34%) –
Multiple myeloma 7 (1.89%) 38 (0.93%) 2.03 (0.91–4.55)
Esophageal cancer 3 (0.81%) 60 (1.46%) 0.55 (0.17–1.75)
Laryngeal cancer 3 (0.81%) 51 (1.24%) 0.65 (0.2–2.08)
Liver cancer 20 (5.39%) 56 (1.36%) 3.93 (2.36–6.55)
Brain cancer 6 (1.62%) 64 (1.56%) 1.03 (0.45–2.38)
Kidney cancer 3 (0.81%) 55 (1.34%) 0.6 (0.19–1.92)
Pharyngeal cancer 13 (3.5%) 76 (1.85%) 1.88 (1.04–3.39)
Corpus uteri cncer 5 (1.35%) 46 (1.12%) 1.2 (0.48–3.02)
Stomach cancer 6 (1.62%) 80 (1.95%) 0.83 (0.36–1.9)
Leukemia 13 (3.5%) 89 (2.17%) 1.61 (0.9–2.88)
Ovarian cancer 5 (1.35%) 56 (1.36%) 0.98 (0.39–2.45)
Pancreatic cancer 16 (4.31%) 109 (2.66%) 1.62 (0.96–2.74)
Malignant melanoma 4 (1.08%) 106 (2.58%) 0.42 (0.15–1.14)
Urinary tract cancer 8 (2.16%) 146 (3.56%) 0.6 (0.29–1.22)
Cervical cancer 2 (0.54%) 32 (0.78%) 0.69 (0.17–2.88)
Prostate cancer 40 (10.78%) 559 (13.62%) 0.79 (0.57–1.09)
Breast cancer 21 (5.66%) 293 (7.14%) 0.79 (0.51–1.23)
Colon cancer 43 (11.59%) 533 (12.99%) 0.89 (0.65–1.21)
Lung cancer 53 (14.29%) 502 (12.23%) 1.16 (0.87–1.54)
Skin cancer 84 (22.64%) 983 (23.96%) 0.94 (0.75–1.17)
Other cancer 5 (1.35%) 48 (1.17%) 1.15 (0.46–2.89)
SAB = Staphylococcus aureus bacteremia.
Table 4
Incidence rate and ratio of cancer for individuals with and without Staphylococcus aureus.
Cancer per 100000 PYs with 95% CI SAB cohort Cancer per 100000 PYs with 95% CI Population cohort Crude IRR (95% CI)
Sex
Male 4.07 (3.35–4.89) 2.48 (2.30–2.68) 1.64 (1.31–1.98)
Female 3.28 (2.46–4.30) 1.93 (1.72–2.17) 1.69 (1.23–2.23)
Age group
0-15 0.68 (0.14–2.00) 0.05 (0.01–0.16) 13.6 (2.27–81.39)
16-35 1.29 (0.47–2.80) 0.04 (0.01–0.15) 32.2 (6.5–159.79)
36-55 1.64 (0.95–2.62) 0.68 (0.53–0.86) 2.43 (1.27–3.90)
56-75 4.71 (3.73–5.88) 3.39 (3.11–3.69) 1.39 (1.08–1.74)
> 75 7.91 (6.05–10.2) 5.41 (4.85–6.01) 1.47 (1.09–1.89)
mCCI score
∗
0 2.88 (2.14–3.79) 1.86 (1.71–2.01) 1.55 (1.12–2.02)
1–2 3.75 (2.89–4.79) 3.55 (3.15–3.98) 1.06 (0.80–1.37)
> 2 5.51 (4.10–7.25) 5.69 (4.29–7.41) 0.98 (0.65–1.41)
∗
mCCI score=modified Charlson Comorbidity score (without cancer or metastasis).
SAB = Staphylococcus aureus bacteremia, PY = personyears, CI = confidence interval, IRR = incidence rate ratio.
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Clostridium species and colorectal cancer[22–24] have been shown
as well as between Salmonella typhi infection and gallbladder
cancer,[25] between Chlamydia pneumoniae and lung cancer,[26]
between Bartonella species and vascular tumors,[27] and between
Gram negative bacteria and prostate cancer.[28] A recent study of
elderly adults with sepsis of any cause found increased risk of 7
cancers including liver, cervix, and leukemia.[29] The study
differs in design and analysis from our study; microbiological
etiologies of sepsis were not reported and individual follow-up
was left-censored for the first year, i.e., the study reported cancers
that occurred more than 12 months after the diagnosis of sepsis.
In our cohort, the risk of cancer beyond 1 year was comparable to
the comparison cohort. However, our study did show an almost
4-fold late increased risk of liver cancer similar to Liu et al. To our
knowledge no other study has described an association between
S. aureus bacteremia and risk of cervical cancer, multiple
myeloma, leukemia, sarcoma, liver cancer, pancreatic cancer, or
urinary tract cancer.
4.3. Implication and explanation of findings
Several mechanisms may explain the increased risk of cancer after
SAB. Firstly, cancer-related immune suppression may occur
through either general immune hyporesponsiveness induced by
the cancer per se or by malignant transformation of immune cells.
In support of the latter, we found that the risk of leukemia and
multiple myeloma were increased. The previously described
association between an increased risk of bacteremia in patients
with hematological malignancy as well as between invasive
pneumococcal disease and subsequent multiple myeloma is
consistent with our findings.[30–32] However, to our knowledge
this is the first report of an increased risk of hematological
malignancy following SAB. While the pathophysiology is
unknown it is obvious to speculate that the risk may be caused
by a failing production of immune effector cells and immuno-
globulin.
4.4. Strengths and limitations
Our study has several strengths including the nationwide
population-based design with complete follow-up, its size, and
the uniqueDanish registration system that enables linkage of data
for each individual in the study to a randomly selected and
matched population comparison cohort. Potential limitations
include reliance on register data that may contain errors but
misclassification would occur in both cases and controls, and,
thus, be non-differential. Infection following invasive diagnostic
procedures or detection due to increased diagnostic work-up
related to SAB could explain part of the increased risk
associations observed. In fact, an increased risk in the case
cohort was observed for 14 of the 27 cancer groups in the first 3
months after discharge for SAB. In order to account for detection
bias the case and population cohorts were left-censored for the
first 3 months. However, the risk differed substantially among
various cancer types arguing against increased general diagnostic
surveillance as being the main explanation for our findings. Our
dataset did not include information on lifestyle factors such as
smoking and alcohol use or socioeconomics that affect life
expectancy and susceptibility to infection or cancer. Residual
confounding related to these and other factors cannot be excluded.
4.5. Conclusion, recommendation, and future directions
Our study aimed to clarify the role of SAB as a marker of occult
cancer. The impact of the increased risk in absolute numbers is
small, and therefore further work-up to diagnose cancer of
patients in general after SABmay not be cost-effective. The results
suggest, however, that diagnostic work-up for an occult cancer
may be appropriate for some patients based on an individualized
assessment. Specifically, this may include screening of individuals
with concomitant anemia or hypercalcaemia by either determin-
ing a white blood cell differential or protein electroforesis that
Figure 3. A-C. Cumulative incidence of cancer in the case and population
cohorts according to the level of prior comorbidity. 2A: no comorbidity; 2B:
intermediate level of comorbidity; and 2C: high level of comorbidity.
Gotland et al. Medicine (2020) 99:17 Medicine
6
may permit earlier detection of hematological malignancy.
Further, younger individuals without prior comorbidity who
develop SAB may be candidates for extended follow-up.
The risk of primary incident cancer was 65% higher in the SAB
cohort compared to the population cohort during the first year of
follow-up and included 7 specific cancers. Screening for these
specific cancers in selected populations may allow for earlier
detection.
Finally, our findings should be interpreted with caution
because we are unable to exclude reverse causation due to the
study design.
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